Table 2.
Permanent discontinuations and adherence in eplerenone- and placebo-treated patients
| Adherence measure/Population | Eplerenone, n (%) | Placebo, n (%) | Risk Difference (95% CI) (percentage points) |
|---|---|---|---|
| Permanent discontinuation for hyperkalemia or hypotension | |||
| Per protocol | 3 (4.0) | 2 (2.8) | 1.2 (−4.7 to 7.1) |
| Intention-to-treat | 3 (3.9) | 2 (2.6) | 1.3 (−4.3 to 6.9) |
| Permanent discontinuation for any cause | |||
| Per protocol | 14 (18.7) | 9 (12.7) | 6.0 (−5.7 to 17.7) |
| Intention-to-treat | 16 (20.8) | 15 (19.5) | 1.3 (−11.4 to 14.0) |
| Took ≥80% of prescribed dose at every visit | |||
| Per protocol | 60 (80.0) | 59 (83.1) | −3.1 (−15.7 to 9.5) |
| Intention-to-treat | 61 (79.2) | 60 (77.9) | 1.3 (−11.7 to 14.3) |
The per protocol population included 75 eplerenone-treated patients and 71 placebo-treated patients while the intention-to-treat population included 77 patients in each group. 95% CI, 95% confidence interval.